MDxHealth (MDXH) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MDxHealth in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDXH shares.
View MDXH analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 1 year price targets for MDxHealth's stock. Their MDXH share price forecasts range from $7.00 to $10.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 193.0% from the stock's current price.
View analysts price targets for MDXH or view top-rated stocks among Wall Street analysts.

MDxHealth's stock was trading at $6.61 at the start of the year. Since then, MDXH shares have decreased by 58.7% and is now trading at $2.73.
View the best growth stocks for 2023 here.

MDxHealth saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 35,200 shares, a decline of 59.7% from the August 15th total of 87,300 shares. Based on an average daily trading volume, of 95,000 shares, the short-interest ratio is currently 0.4 days. Currently, 0.1% of the company's shares are short sold.
View MDxHealth's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our MDXH earnings forecast.

MDxHealth SA (NASDAQ:MDXH) released its quarterly earnings results on Wednesday, August, 23rd. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.02. The firm had revenue of $16.75 million for the quarter, compared to the consensus estimate of $15.14 million. MDxHealth had a negative net margin of 87.00% and a negative trailing twelve-month return on equity of 203.05%.

MDxHealth issued an update on its FY 2023 earnings guidance on Thursday, August, 24th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $65.00 million-$70.00 million, compared to the consensus revenue estimate of $65.30 million.

(MDXH) raised $45 million in an IPO on Thursday, November 4th 2021. The company issued 3,750,000 shares at $12.00 per share.

MDxHealth trades on the NASDAQ under the ticker symbol "MDXH."

MDxHealth's stock is owned by many different institutional and retail investors. Top institutional investors include Perkins Capital Management Inc. (1.49%), Sei Investments Co. (0.75%), Renaissance Technologies LLC (0.11%), Citadel Advisors LLC (0.08%) and BerganKDV Wealth Management LLC (0.04%).
View institutional ownership trends.

Shares of MDXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MDXH stock can currently be purchased for approximately $2.73.

MDxHealth (NASDAQ:MDXH) has a market capitalization of $73.82 million and generates $37.05 million in revenue each year. The company earns $-44,040,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis.

The company employs 252 workers across the globe.

MDxHealth's mailing address is CAP Business Center, Herstal, Liege 4040. The official website for the company is mdxhealth.com. The company can be reached via phone at 324-364-2070 or via email at ir@mdxhealth.com.